RAS inhibitor Abd-7

Name: RAS inhibitor Abd-7
Brand: MedChemExpress
SKU: HY-122862
Rating: 5.0 (3 reviews)

製品番号: HY-122862 純度: 99.57%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

RAS inhibitor Abd-7, a potent RAS-binding compound (K_d=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

RAS inhibitor Abd-7 構造式

CAS 番号 : 2351843-48-4

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 385	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 385	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$350	在庫あり	Estimated Time of Arrival: December 31
10 mg	$550	在庫あり	Estimated Time of Arrival: December 31
25 mg	$950	在庫あり	Estimated Time of Arrival: December 31
50 mg	$1450	在庫あり	Estimated Time of Arrival: December 31
100 mg	$2250	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

顧客検証

Ras アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

K-Ras H-Ras N-Ras Ras

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	8 3 Compound: Abd-7	Cytotoxicity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 34520956]
DLD-1	IC₅₀	8 3 Compound: 39; Abd-7	Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant incubated for 72 hrs by CellTitreGlo assay Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant incubated for 72 hrs by CellTitreGlo assay	[PMID: 33225706]
DLD-1	IC₅₀	8 3 Compound: 39; Abd-7	Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant incubated for 72 hrs by CellTitreGlo assay Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant incubated for 72 hrs by CellTitreGlo assay	[PMID: 33225706]
DLD-1	IC₅₀	8 3 Compound: 39; Abd-7	Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant incubated for 72 hrs by CellTitreGlo assay Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant incubated for 72 hrs by CellTitreGlo assay	[PMID: 33225706]
DLD-1	IC₅₀	8 3 Compound: Abd-7	Cytotoxicity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 34520956]
DLD-1	IC₅₀	8 3 Compound: Abd-7	Cytotoxicity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 34520956]
HT-1080	IC₅₀	10 3 Compound: Abd-7	Cytotoxicity against human HT-1080 cells harboring NRAS Q61K mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human HT-1080 cells harboring NRAS Q61K mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 34520956]
HT-1080	IC₅₀	10 3 Compound: Abd-7	Cytotoxicity against human HT-1080 cells harboring NRAS Q61K mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human HT-1080 cells harboring NRAS Q61K mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 34520956]
HT-1080	IC₅₀	10 3 Compound: Abd-7	Cytotoxicity against human HT-1080 cells harboring NRAS Q61K mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human HT-1080 cells harboring NRAS Q61K mutant assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo luminescent cell viability assay	[PMID: 34520956]

体外実験

RAS inhibitor Abd-7 (0-20 μM; 24-48 hours) is a cell-potent inhibitor affecting the viability of cancer cell lines in a single digit to low micromolar range^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	DLD-1 cells, HT1080 cells
Concentration:	0-20 μM
Incubation Time:	24-48 hours
Result:	The IC₅₀ of 8 μM in DLD-1 and 10 μM in HT1080 at 72 h (similar values for the IC₅₀ were found after 48 h).

分子量

391.46

分子式

C₂₃H₂₅N₃O₃

CAS 番号

2351843-48-4

Appearance

Solid

Color

Off-white to light yellow

SMILES

COC1=NC(C2=C3C(OCCO3)=CC=C2)=CC=C1NC4=CC=C(CN(C)C)C=C4

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (319.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5545 mL	12.7727 mL	25.5454 mL
5 mM	0.5109 mL	2.5545 mL	5.1091 mL
10 mM	0.2555 mL	1.2773 mL	2.5545 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.31 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.57%

Select Batch:

データシート (277 KB) SDS (251 KB)

COA (254 KB) HNMR (225 KB) LCMS (95 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Quevedo CE, et al. Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Nat Commun. 2018;9(1):3169. Published 2018 Aug 9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5545 mL	12.7727 mL	25.5454 mL	63.8635 mL
	5 mM	0.5109 mL	2.5545 mL	5.1091 mL	12.7727 mL
	10 mM	0.2555 mL	1.2773 mL	2.5545 mL	6.3863 mL
	15 mM	0.1703 mL	0.8515 mL	1.7030 mL	4.2576 mL
	20 mM	0.1277 mL	0.6386 mL	1.2773 mL	3.1932 mL
	25 mM	0.1022 mL	0.5109 mL	1.0218 mL	2.5545 mL
	30 mM	0.0852 mL	0.4258 mL	0.8515 mL	2.1288 mL
	40 mM	0.0639 mL	0.3193 mL	0.6386 mL	1.5966 mL
	50 mM	0.0511 mL	0.2555 mL	0.5109 mL	1.2773 mL
	60 mM	0.0426 mL	0.2129 mL	0.4258 mL	1.0644 mL
	80 mM	0.0319 mL	0.1597 mL	0.3193 mL	0.7983 mL
	100 mM	0.0255 mL	0.1277 mL	0.2555 mL	0.6386 mL